Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

By The Northwire Desk — AI Analysis Feb 17, 2026 · 08:00 ZCT · 0.175 Zero Candida Technologies Inc.
ZCT · Price

Executive Summary

  • Zero Candida Technologies announced scaling production to 250 ISO 13485‑certified clinical‑grade prototypes of its ZC‑001 therapeutic device.
  • The additional units will support GLP preclinical testing and keep the company on track for a Q4 2026 clinical study involving at least 100 women.
  • Completion of the 250‑unit run is expected within 90 days, marking a key step toward human trials and market entry.

Key Details

  • Production Scale‑Up: Manufacturing increased to 250 clinical‑grade prototypes under ISO 13485 quality standards.
  • Timeline: All 250 units to be completed within the next 90 days.
  • Regulatory Pathway: Prototypes will support Good Laboratory Practice (GLP) preclinical testing, a prerequisite for IND filing and subsequent human trials.
  • Clinical Study Plan: Targeted Q4 2026 clinical study enrolling ≥100 women to evaluate efficacy of ZC‑001 in treating recurrent vulvovaginal candidiasis (VVC).
  • Preclinical Performance: Prior laboratory tests demonstrated 99.999% fungal eradication under controlled conditions.
  • Device Overview: ZC‑001 is a SMART, AI‑enabled therapeutic device combining precision blue‑light therapy, targeted drug delivery, and wireless diagnostics for at‑home treatment of VVC.
  • Market Context: VVC treatment market projected to exceed US $2 billion by 2030; recurrent cases are increasingly drug‑resistant.

Notable Quotes

“Scaling volume helps us transition from laboratory validation to human studies more efficiently and demonstrates our commitment to medical‑grade excellence,” – Eli Ben‑Haroosh, CEO.

Read the original news release →

More from Zero Candida Technologies Inc.

Jun 24, 2026 · 08:00

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Other Oct 20, 2025 · 09:00

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Production / Operations